NEW YORK, NY / ACCESSWIRE / May 27, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Gossamer Bio, Inc. (NASDAQ:GOSS)
CONTACT JAKUBOWITZ ABOUT GOSS:
https://claimyourloss.com/securities/gossamer-bio-inc-loss-submission-form/?id=6930&from=1
The GOSS lawsuit is on behalf of investors who purchased GOSS common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer's documents issued in connection with its February 8, 2019 initial public offering.
Lead Plaintiff Deadline: June 2, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose: (1) the reasons for Gossamer's GB001 trial failures; (2) the purported clinical validation of Novartis' oral DP2 antagonist; and (3) that, as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Groupon, Inc. (NASDAQ:GRPN)
CONTACT JAKUBOWITZ ABOUT GRPN:
https://claimyourloss.com/securities/groupon-inc-loss-submission-form/?id=6930&from=1
Class Period: November 4, 2019 - February 18, 2020
Lead Plaintiff Deadline: June 29, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing fewer customer engagements in its Goods category; (2) Groupon relied on its Goods category to drive its sales, especially during the holiday season; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
CytomX Therapeutics, Inc. (NASDAQ:CTMX)
CONTACT JAKUBOWITZ ABOUT CTMX:
https://claimyourloss.com/securities/cytomx-therapeutics-inc-loss-submission-form/?id=6930&from=1
Class Period: May 17, 2018 - May 13, 2020
Lead Plaintiff Deadline: July 20, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887
SOURCE: Jakubowitz Law
View source version on accesswire.com:
https://www.accesswire.com/591652/LAWSUITS-FILED-AGAINST-GOSS-GRPN-and-CTMX--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS
